Baxter Healthcare Corp. has expanded lyophilization capacity at its Halle, Germany facility to support the growth of its Baxter BioPharma Solutions (BPS) cytotoxic contract manufacturing business. Two large-scale lyophilization chambers will be added to freeze-dry cancer therapies for its pharma and biopharma partners. The expansion will be complete and fully validated by mid-2007. “We are expanding to meet the growing demands of the cytotoxic manufacturing market,” said Tom Pol...